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Objective: The transdiagnostic cognitive behavioral treatments for 
treating the coexistence of anxiety and mood disorders received useful 
empirical supports in the recent years. However, these treatments still 
have moderate efficacy. Following the improvements and developments 
in transdiagnostic protocols and considering the importance of repetitive 
negative thinking as a core transdiagnostic factor in emotional disorders, 
this study examined a new form of transdiagnostic treatment based on 
Repetitive Negative Thinking (TTRNT) of co-occurrence of anxiety and 
depressive disorders. 
Methods: Treatment efficacy was assessed using single case series with 
multiple baselines. Three patients meeting the criteria for co-occurrence 
of anxiety and depressive disorders were selected using the Anxiety 
Disorders Interview Schedule for DSM-IV. The patients were treated 
individually for 12 weekly sessions. Participants completed the 
standardized outcome measures during the baseline, treatment and one-
month follow-up. 
Results: At post-treatment, all participants showed significant clinical 
changes on a range of standardized outcome measures, and these gains 
were largely maintained through the one-month follow-up both in the 
principle and co-principal diagnosis. 
Conclusions: Although the results of this preliminary investigation 
indicated that TTRNT could be a time effective and efficient treatment for 
individuals with co-occurrence of anxiety and depressive disorders, 
further controlled clinical trials are necessary to examine this new 
treatment approach. 
 
Keywords: Transdiagnostic Treatment, Repetitive Negative Thinking, Anxiety, 
Depression. 
 
 
 
psychological treatments. One of the main problems 
faced by specific cognitive-behavioral therapies is the 
comorbidity of anxiety and mood disorders (13). 
Due to complications caused by comorbidity, using this 
specific therapeutic protocol is not efficient for several 
reasons. First, high level of comorbidity of anxiety and 
mood disorders provokes patients’ withdrawal during 
specific cognitive behavioral therapies and reduces 
patient compliance to finish their treatment. Second, 
comorbidity of anxiety and mood disorders lowers the 
efficacy of specific cognitive behavioral therapies since 
using several therapeutic protocols for patients with co-
occurrence of anxiety and mood disorders is not 
economically efficient, and these patients cannot afford 
to finish their treatment. Third, coexistence of anxiety 
and mood disorders raises severe dangers including 
risk of suicide in patients and requires serious 
interventions (14-16). 
 
 
 
 
 
 
Approaching comorbidity of anxiety and mood 
disorders and resolving previously mentioned 
challenges is only possible by developing methods that 
consider comorbidity at both theoretical and practical 
levels. Transdiagnostic therapies are leading in this 
new approach toward development of therapeutic 
protocols. Transdiagnostic approaches are trying to 
resolve therapeutic problems and challenges arising 
from comorbidity by studying theoretical nature of 
comorbidity and recognizing common aspects of 
emotional disorders particularly anxiety and depression 
disorders (17-21; 15, 16). 
Based on the review article on transdiagnostic 
therapies, early published transdiagnostic therapies 
were pragmatic. These therapies were the first attempts 
to treat comorbidity anxiety and mood disorders. These 
protocols are mainly based on clinical experiences and 
common and similar techniques of specific cognitive 
behavioral therapies and concentrate on common 
symptoms of anxiety and depression disorders. Several 
studies have shown the effect of pragmatic 
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transdiagnostic therapies in treating emotional 
disorders. However, results of most of transdiagnostic 
therapies implicate the moderate effectiveness of these 
therapeutic protocols. Based on this meta-analysis, the 
most important justification for the moderate 
effectiveness of pragmatic transdiagnostic protocols is 
its disregard for common cognitive-behavioral 
mechanisms of emotional disorders (16, 18, 19, 22, 
23).  
Moderate effectiveness of pragmatic transdiagnostic 
therapies led to designing protocols that had other 
foundations. Therefore, Barlow et al. (24) made a 
considerable improvement in designing theoretical-
practical transdiagnostic protocols through several 
studies with emphasis on the role of ‘emotion 
regulation’ as the main cognitive-behavioral 
mechanism in emotional disorders. This protocol is 
more effective than other pragmatic transdiagnostic 
therapeutic protocols since it has a greater theoretical 
basis. Although in Barlow’s model, theory and therapy 
come together and ‘emotion regulation’ is considered 
and emphasized in the context of treatment, yet it does 
not sufficiently match with the theoretical knowledge 
of common psychopathology of emotional disorders 
(24-26). 
Recent studies have shown that repetitive negative 
thinking is the most important common cognitive 
behavioral process in formation and continuation of 
emotional disorders. Repetitive negative thinking 
includes worry, rumination, treatment monitoring, 
obsessions and any other kind of repetitive negative 
thoughts which is the core of depression and anxiety 
disorders. Surveying more than 50 studies in cognitive 
pathology of emotional disorders shows that repetitive 
negative thinking is the main transdiagnostic factor in 
more than 13 diagnostic classes, including depression 
disorders, anxiety disorders, sleep disorder, eating 
disorder, substance abuse disorder and schizophrenic 
disorder (17-32). 
Considering these studies, One potential way to 
improve the efficacy of pragmatic transdiagnostic 
therapies and Barlow’s transdiagnostic therapy (24) for 
co-occurrence of anxiety and depressive disorders is to 
adapt transdiagnostic therapies to specifically address 
repetitive negative thinking as core transdiagnostic 
processes underlying emotional disorders. One of the 
possible deficits of this is their disregard for repetitive 
negative thinking as the core process underlying 
emotional disorders in the context of their therapeutic 
protocols. Following the improvements and 
developments in transdiagnostic protocols and 
considering the importance of repetitive negative 
thinking in formation and continuation of emotional 
disorders and considering the lack of a transdiagnostic 
protocol based on this fundamental process, Akbari et 
al. (33) attempted to develop an initial design of a 
transdiagnostic treatment based on repetitive negative 
thinking (TTRNT) to be used for patients with co-
occurrence of anxiety and depressive disorders. Thus, 
the aim of the current study was to use a single case 
series to establish the preliminary evidence of whether 
TTRNT has the potential to be an efficacious therapy 
for co-occurrence of anxiety and depressive disorders. 
 
Material and Methods 
 
Design 
This case series employed an AB replication across 
patients design with follow-up to evaluate the 
effectiveness of TTRNT for people with co-occurrence 
of anxiety and depressive disorders. Replication across 
three patients with different co-occurrence of anxiety 
and depressive disorders presentations constitutes a 
‘direct replication’ (34) and begins to establish the 
generalizability of treatment efficacy across the 
disorder. This is especially important in co-occurrence 
of anxiety and depressive disorders as the clinical 
presentation which is markedly heterogeneous. Patients 
were assigned into no-treatment baselines for three 
weeks until stability was established at baseline. 
Patients met with the therapist on a weekly basis for 15 
minutes during the baseline to complete outcome 
measures. No therapeutic input occurred during these 
meetings. Following the baseline period, TTRNT was 
delivered weekly, with each treatment sessions lasting 
no longer than one hour. Following the treatment, 
patients were followed up in one month; no additional 
treatment was delivered during the follow-up period. 
Patients 
Three patients, who consecutively referred to 
Counseling and Psychological Services Center of 
Sharif University to receive treatment for co-
occurrence of anxiety and depressive disorders, were 
included in the study. Patients initially completed a 
written informed consent, and were then assessed using 
The Anxiety Disorders Interview Schedule for DSM-
IV (ADIS-IV) and were included in the study if they 
met the following inclusion criteria: Having the 
diagnostic criteria of more than one for co-occurrence 
of anxiety and depressive disorders including 
generalized anxiety disorder, obsessive compulsive 
disorder, panic disorder, social anxiety, dysthymic and 
major depressive disorder for at least one year; aged 
18–65; patient consent to participate in the research; 
medication free or stable on medication (i.e., three 
months without a change in medication type and dose). 
The exclusion criteria were as follows: The evidence of 
a psychotic disorder, bipolar disorders, substance 
abuse; receiving concurrent psychological treatment; 
having cognitive behavior therapy, behavior therapy or 
cognitive therapy in the two years preceding referral; 
and evidence of a serious problem during the study 
such as suicidal thoughts or change in rates of 
psychotropic medications dose . 
Instrument     
Anxiety Disorders Interview Schedule for DSM-IV 
(ADIS-IV; 35) 
The ADIS-IV is a structured diagnostic interview 
designed to assess the presence, nature, and severity of 
DSM-IV anxiety, mood, and somatoform and 
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substance use disorders. Brown, DiNardo, Lehman, and 
Campbell (35) provided evidence of acceptable inter-
rater reliability for the anxiety disorders investigated in 
the present study (k = .59 – .79). Inter-rater reliability 
(k = .63) for the combined depressive disorders group 
(major depressive disorder and dysthymic) was also 
acceptable. Evidence of construct validity, including 
discriminant and convergent validity, has been 
demonstrated (35). Principal and additional diagnoses 
are assigned a clinical severity rating (CSR) on a scale 
from 0 (no symptoms) to 8 (extremely severe 
symptoms), with a rating of 4 or above (definitely 
disturbing/disabling) passing the clinical threshold for 
DSM-IV diagnostic criteria. This measure has 
demonstrated excellent to acceptable inter-rater 
reliability for the anxiety and mood disorders (35). The 
full ADIS-IV-L (focusing on current and lifetime 
diagnoses) was administered only at the original intake. 
An abbreviated version of the ADIS, focusing only on 
current symptomatology (Mini-ADIS-IV; 35) was 
administered at post-treatment and follow-up. This 
measure has demonstrated acceptable to excellent inter-
rater reliability for the anxiety and mood disorders in 
Iranian samples (36). 
Beck Depression Inventory-II (BDI-II; 37) 
The BDI-II is a 21-item measure to assess current 
depressive symptoms, and was included as a general 
measure of depressive symptoms across the disorders. 
Internal consistency (α = .92) and test re-test reliability 
(r = .93 over 1 week) are established (37), and evidence 
for construct validity has been demonstrated (38). 
Psychometric features of revised form of this 
questionnaire have been obtained by Ghasemzadeh, et 
al. (39) in Iran. The results indicate excellent internal 
consistency (α = .87) and acceptable test-retest 
reliability (r = .74 over 1 week) 
Beck Anxiety Inventory (BAI; 40) 
The BAI was included as a general measure of anxiety-
related symptoms across the disorders. The BAI also 
contains 21 items scored in a similar way and focuses 
on common symptoms that are more unique to anxiety, 
such as somatic and certain cognitive symptoms. The 
reliability and validity of the BAI Farsi translated 
version was demonstrated by Fata et al. (41) in Iranian 
samples. The results indicate excellent internal 
consistency (α = .92) and good temporal stability (r = 
.81 over 1 week). 
Positive and Negative Affect Scale (PANAS; 42) 
The PANAS was included to assess the levels of 
positive and negative affect across the disorders. The 
PANAS is a brief, reliable, and valid self-report 
measure of positive and negative affect. It consists of 
20 feeling or emotion words. Respondents rate each 
emotion word on a scale ranging from 1 (very slightly 
or not at all) to 5 (extremely), indicating the extent to 
which they experienced that emotion or feeling during 
the past few weeks. The PANAS allows for the 
assessment of core negative affect as well as deficits in 
positive affect. The PANAS has shown excellent 
convergent and divergent validity. The reliability and 
validity of the PANAS Farsi translated version was 
demonstrated by Bakhshipour (43) in Iranian samples. 
He showed that alpha coefficient was .87. The results 
indicate PANAS has construct validity. 
Repetitive Thinking Questionnaire (RNQ; 44) 
The RTQ is a 31-item self-report measure of 
transdiagnostic repetitive negative thinking. Items were 
drawn from the Penn State Worry Questionnaire (45), 
the Ruminative Responses Scale of the Response 
Styles Questionnaire (46) and the Post-Event 
Processing Questionnaire-Revised (47) and were 
modified to remove diagnosis-specific content. The 
questionnaire comprises two subscales; Repetitive 
Negative Thinking (27 items) and Absence of 
Repetitive Thinking (4 items). This tool demonstrated 
the factor structure, internal consistency (α = .72–.93), 
convergent validity, and predictive utility of the RTQ 
in a student sample (44). In Iran, Khaleghi et al. (48) 
has reported the internal consistency of 0.89. Similarly, 
the rates of correlation for BAI and BDI-II were .53 
and .52, respectively. 
Work and Social Adjustment Scale (WSAS; 49) 
The WSAS is a 5-item measure asking participants to 
rate the degree of interference caused by their 
symptoms in work, home management, private leisure, 
social leisure, and family relationships. Interference is 
rated over the past week on a 0 to 8 scale (0 = not at all 
interfering to 8 = severe interference). The WSAS is a 
descriptive measure of subjective interference in 
various domains of living. The final score represents 
the average of scores across domains. The WSAS has 
shown adequate internal consistency, ranging from 
0.70 to 0.94, and test-retest correlation (0.73) in a 
clinical sample (50). Psychometric features of revised 
form of this questionnaire have been obtained by 
Solimani, et al. (51) in Iran. The results indicate 
acceptable test-retest reliability (r = .69 over 1 week). 
Similarly, the rates of correlation for WSAS and the 
Depression, Anxiety and Stress Scales (DASS) were 
.66. (51) 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS; 52) 
The Y-BOCS is a semi-structured interview designed 
to measure the severity of OCD symptoms. The 
severity scale is comprised of 10 items, 5 items 
measuring the severity of obsessions and 5 measuring 
the severity of compulsions. Each item is rated on a 5 
point scale ranging from 0 (none) to 4 (extreme) giving 
a maximum total score of 40. The Y-BOCS has 
become the ‘gold standard’ assessment measure in 
treatment outcome research in OCD. It has been shown 
to have reasonable psychometric properties and 
sensitivity to treatment effects (53, 54). The reliability 
and validity of the BDD-YBOCS Farsi translated 
version was demonstrated by Rabiei, Khormdel, 
Kalantari, and Molavi (55) in both healthy and clinical 
samples. They showed that alpha coefficients ranged 
from .78 to .93 for the BDD-YBOCS total score and 
for its subscales. 
Penn-State Worry Questionnaire (PSWQ; 45) 
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The PSWQ is a widely used 16-item measure of worry 
with excellent internal consistency (α = .86–.95) and 
good temporal stability (r = .92 over 8–10 weeks and r 
= .74–.93 over 4 weeks; 45, 56). The measure has 
demonstrated the evidence of construct validity in 
clinical and community populations (57, 58). The 
PSWQ has become the ‘gold standard’ assessment 
measure in treatment outcome research in GAD. It has 
been shown to have reasonable psychometric properties 
and is sensitive to treatment effects (59, 60). 
Psychometric features of this questionnaire have been 
obtained by Shirinzade, et al. (61) in Iran. The results 
indicate excellent internal consistency (α = .86) and 
good temporal stability (r = .90 over 4 weeks). 
Procedure 
Patients completed the BAI, BDI and WSAS at all 
baseline and treatment sessions and at follow-up. The 
PANAS, PSWQ, Y-BOCS and RNTQ were completed 
at the first baseline session, post treatment and 1-month 
follow-up. All patients would be offered 12 one hour 
sessions of TTRNT. After the baseline phase, patients 
received treatment. In the current study, assessment of 
the tools used in research was performed by a trained 
assessor. The assessor was not permitted to act as a 
therapist for the same case, but acted as an assessor at 
post-treatment and follow-up. The assessor was blind 
to the study  . 
Treatment 
The transdiagnostic therapy based on repetitive 
negative thinking (33) is a flexible, modular-based 
individual treatment protocol. The procedure of the 
protocol design in summary is as follows: Akbari et al. 
(33) first, incorporated repetitive negative thinking and 
its relevant variables into Barlow’s transdiagnostic 
protocol and then consulted with national and 
international experts in transdiagnostic therapies and at 
the end, redesigned Barlow’s transdiagnostic protocol 
based on repetitive negative thinking. The treatment 
protocol was approved by an institutional review board. 
Finally, this protocol was designed in six modules that 
usually take 12 one-hour sessions to administer. 
Therapeutic sessions are held weekly. Similar to most 
of the cognitive behavioral therapeutic protocols, 
sessions are started by reviewing previous homework.  
After reviewing, basic and doable concepts are 
presented in the session in order for the patient to be 
familiar with therapeutic skills. Direct training and 
cooperative empiricism constitute the main part of the 
therapeutic sessions. In the end of each session, the 
homework that should be done for the next session is 
discussed. Each module of therapy usually takes 2 
sessions and some modules are emphasized based on 
the type of the disorder. In the following, a brief 
description of each therapeutic module is presented .
The therapist for the study was a doctoral student with 
4 years of experience, who provided treatment under 
the close supervision of a licensed senior team 
member. Treatment adherence was monitored during 
weekly supervision and manual development meetings.  
Sessions were audio-taped to facilitate supervision and 
monitor adherence. 
Module 1: Familiarity with Emotional Disorders and 
Transdiagnostic Therapy 
The main purpose of this module is the client’s general 
awareness of emotional disorders and the necessity of 
utilizing transdiagnostic therapy for his/her co-
occurrence of emotional disorders (24). The main part 
consists of familiarizing the client with treatment 
procedure, nature of negative and unpleasant emotions 
and their destructive effect on people’s performance. 
During this module, the patient is expected to gain 
more consciousness about the symptoms of his/her 
emotional disorders and their simultaneity and 
understand the essential role of the transdiagnostic 
therapy for his/her co-occurrence disorder. 
Module 2: Emotional Self-Awareness and Emotional 
Mindfulness 
General objectives of this module include teaching 
emotional self-awareness and emotional mindfulness 
skills (24). Content of the first objective is 
psychological training in nature of emotions, main 
components of emotional experience in order for the 
patient to gain a better understanding of his/her 
negative emotions and emotional response patterns by 
searching and monitoring his/her emotional 
experiences. Content of the second objective of this 
module is the emotional mindfulness skill which means 
that the patient can experience his/her negative 
emotions without judgment or inhibition. In this 
module of therapy, the therapist reminds the client that 
emotions are similar to sea waves as they come, soar 
and plummet so he/she could identify their presence 
and let these emotions go . 
Module 3: Familiarity with Repetitive Negative 
Thinking and Guidelines to Decrease It  
The main objectives of this module include familiarity 
with repetitive negative thinking, practicing attention-
training technique (62) and practicing detached 
mindfulness technique (62) in order to reduce repetitive 
negative thinking. In this module, first, the therapist 
tries to familiarize the patient with repetitive negative 
thinking as the main transdiagnostic element in anxiety 
and depression disorders and describes this mechanism 
in concept of rumination, worry, preoccupation, 
fixation of attention on threat, self-monitoring and any 
other sort of repetitive negative thinking. After 
describing the concept of repetitive thinking and its 
role in emotional disorders, the therapist teaches 
techniques of attention training and detached 
mindfulness to the patient for reducing repetitive and 
stubborn thoughts. During this module, the therapist 
attempts to improve the flexibility of patient’s attention 
and release him/her from repetitive negative thinking 
using these two techniques. 
Module 4: Appraisal Metacognitive Beliefs and 
Reappraisal 
The main objectives of this module include patient’s 
familiarity with metacognitive beliefs about repetitive 
negative thinking and challenging these beliefs (62). At 
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first, the therapist tries to inform the patient about 
negative and positive metacognitive beliefs related to 
repetitive negative thinking and identify them with the 
patient’s help. Then, the therapist challenges negative 
metacognitive beliefs in two areas of uncontrollability 
and repetitive negative thinking, employing verbal 
reattribution and behavioral experiments techniques. 
Finally, after modifying negative metacognitive beliefs, 
the therapist makes an attempt to correct positive 
metacognitive beliefs related to repetitive negative 
thinking and tries to challenge and renovate these 
believes using employing verbal reattribution and 
Behavioral experiments techniques. 
Module 5: Facing Experiential Avoidance 
The main objectives of this module include patient’s 
familiarity with the concept of experiential avoidance 
and training in acceptance and exposure techniques 
(24) for reducing experiential avoidance. First, the 
therapist introduces the experiential avoidance as a 
reluctance to experience unpleasant internal 
experiences (e.g., feelings, sensations, memories and 
impulses) and external experiences (e.g., situations, 
peoples, places) and use of internal and external 
avoidant strategies. Then, in the next step, he helps the 
patient to recognize avoidant strategies. In the final 
stage of this module, the patient learns to overcome 
his/her experiential avoidance using guidelines on 
acceptance and exposure to internal and external 
aspects. 
Module 6: Preventing Relapse 
The main goal of this module is to review general 
therapeutic concepts and discuss the progress of 
therapy (24). The therapist helps the patient to identify 
the ways to sustain the results of therapy and predict 
future potential problems. The patient is encouraged to 
use therapeutic techniques to progress in achieving 
short-term and long-term goals. 
Overview of Data Analysis 
The nature of data analysis in single case research 
continues to be a source of controversy (63). Graphical 
representation and visual inspection of the data remains 
the predominant form of analysis. Parsonson and Baer 
(64) argue that the goal of single case research is to 
detect clear and observable effects and that graphical 
representation and visual inspection means only such 
effects will be observed. It is an appropriate form of 
analysis for preliminary investigations into the efficacy 
of novel treatments. Accordingly, session by session 
scores across baseline, treatment and follow-up on a 
range of self-report measures are presented. 
Furthermore, pre, post and follow-up scores on 
outcome measures are plotted, coupled with the 
percentage improvement made by each patient on each 
measure. 
Clinically Significant across (Co-) Principal Diagnoses 
The clinical significance of changes during treatment 
should be established in order to provide a meaningful 
benchmark of outcome. Jacobson and colleagues (65, 
66) criteria for determining reliable clinical 
improvement and recovery were used to determine the 
proportions of patients meeting these criteria at post-
treatment and follow-up. This criterion requires the 
individual’s score at post-treatment to move from 
outside the range of a clinical group to within the range 
of a ‘functional’ group by crossing a calculated ‘cutoff 
point’ and to demonstrate a statistically reliable change. 
In that study, according to (Co-) Principal (OCD, GAD 
and Dysthymic), standardized criteria were developed 
on the BDI (criterion a; cut-off point =13, reliable 
change index = 7 points) for Dysthymic, the Y-BOCS 
(criterion a; cut-off point-14, reliable change index = 
10 points) for OCD and the PSWQ (criterion a; cut-off 
point = 47, reliable change index = 7 points) for GAD 
and were used to allocate patients with (Co-) Principal 
to one of four possible treatment outcomes: 
deteriorated, unchanged, improved and recovered. 
Asymptomatic Status across (Co-) Principal Diagnoses 
An alternative, but more stringent criterion for defining 
recovery is that patients are asymptomatic following 
treatment. In this study, the defined recovery on the Y-
BOCS (67), PSWQ (68) and BDI-II (38) was as a score 
of 7, 14 and 7 or less, respectively. This criterion was 
applied to each patient at the post-treatment and 
follow-up time points. 
 
Results 
 
Demographical characteristics and clinical symptoms 
of patients are presented in Table 1. 
The distribution of mean baseline, end of therapy 
scores, one-month follow-up scores, baseline to end of 
the therapy change scores and baseline to one-month 
follow-up change scores were markedly skewed for the 
majority of the data. Therefore, the effect sizes were 
calculated for end of the therapy and one-month 
follow-up (s Table 2). Effect sizes (Cohen’s d) were 
calculated by dividing the mean change in individual 
scores (from baseline to end of therapy or one-month 
follow-up) by the pooled standard deviation (SD) of 
scores at these time-points. The pooled standard 
deviation is calculated as√[(SDpre^2+SDpost^2 )/2], 
where ‘pre’ refers to mean baseline scores and ‘post’ to 
end of therapy or follow-up scores. This procedure was 
set out by Cohen (69) and has been used and described 
in other case series (70-72). Cohen (68) identified 
effect sizes as small (d = 0.2), medium (d = 0.5) and 
large (0.8). Graphs were constructed for the weekly 
sessions and at the time-points (baseline, end of 
therapy, one-month follow-up) outcome measures to 
demonstrate detailed changes across the whole course 
of therapy (Figs 1 and 2). 
Each patient’s scores on the BDI, the BAI and the 
PANAS-P, PANAS-N during the baseline and 
treatment phases and at follow-up are shown in Figs. 1 
and 2. The baseline scores for each patient were 
relatively stable across all the outcome measures. Each 
patient showed substantial and relatively rapid 
reductions on the BAI, BDI and PANAS-P, PANAS-N 
over the course of treatment, and these reductions were 
largely maintained at follow-up. There was a slight 
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deterioration at follow-up, but scores continued to 
represent a substantial reduction from baseline. The 
total score on those measures at pre, post and follow-up 
are illustrated in Table 2. The three patients’ pre-
treatment, post-treatment and follow-up scores on the 
WSAS, PSWQ, Y-BOCS and RNTQ are illustrated in 
Fig. 2, and the total score on those measures are shown 
in Table 2.  It can be seen that for each patient, post-
treatment and follow-up scores are substantially lower 
than pre-treatment on all measures. 
Clinical Significant across (Co-) Principal Diagnoses 
At post-treatment and at one-month follow-up, all three 
patients met the standardized recovery criteria for 
principal and co-principal diagnoses on BDI-II 
(criterion a; cut-off point = 13, reliable change index = 
7 points), the Y-BOCS (criterion a; cut-off point-14, 
reliable change index = 10 points) and the PSWQ 
(criterion a; cut-off point = 47, reliable change index = 
7 points). One month follow-up data is available for the 
three participants who maintained recovery. The effect 
size estimates for the ADIS CSR’ (Co-) Principal 
diagnoses for all patients were in the very large range. 
It can be observed that the patients moved from the 
outside range of a “clinical group” to within the range 
of a “functional” group. 
Asymptomatic Status across (Co-) Principal Diagnoses 
When the more stringent outcome criterion of 
asymptomatic status for principal and co-principal 
diagnoses (the score of 7, 14 and 7 or less on Y-BOCS, 
PSWQ and BDI-II) is applied, all patients are 
asymptomatic at post-treatment and at one-month 
follow-up, both in principal and co-principal 
diagnoses. 
Functioning 
There were large effect sizes for an improvement in 
general functioning on the WSAS at end of therapy and 
one-month follow-up. The total mean score on the 
WSAS at end of therapy was also below the identified 
cut-off score of 10 between a clinical and general 
population (Mundt et al., 2002) from above this score 
at baseline. As shown in Fig. 2, the individual graphs 
showing changes on the WSAS indicate that for all 
participants, scores within the baseline period had been 
above an identified clinical mean of 25 (73), and for all 
participants, scores at both end of therapy and one-
month follow-up were below the cut-off score of 10, 
specified by Mundt, Marks, Shear, and Griest (48). 
 
 
Table 1: Demographic Characteristics, Diagnosis Conditions, Treatment History and Medication status of the 
Patients 
 
Medication 
status 
Treatment 
history 
Co-principal 
diagnosis 
Duration of 
principal 
diagnosis 
Principal 
diagnosis 
Marital 
status 
Education Gender Age Patient 
no No 
Dysthymic 
OCD 
4 year GAD Single Bachelor Female 22 1 
Clomipramine 
100 mg daily 
Fluoxetine, 
20 mg daily 
8 sessions 
of CBT at 
3year ago 
GAD 
Dysthymic 
7 year OCD Single Bachelor Male 20 2 
no 
5 sessions 
of CBT at 4 
year ago 
OCD 
GAD 
5 year Dysthymic Single Bachelor Female 23 3 
Note. GAD: Generalized Anxiety Disorder; OCD: Obsession Compulsive Disorder, CBT: Cognitive Behavioral Therapy. 
 
Table 2: Descriptive Statistics and Effect Sizes for Primary Outcome Variables at end of treatment and 1-month 
follow-up 
 
Measure 
Mean baseline 
M(SD) 
End of therapy 
M(SD) 
Effect size 
Pre-post 
1 month follow-up 
M(SD) 
Effect size 
pre-1m FU 
ADIS (Co-)Principal Dx CSR 6.50 (0.6) 2.90 (0.7) 3.91 2.46 (1.08) 3.28 
BDI 28.8 (4.7) 12.3 (3.9) 2.77 14 (3.2) 2.42 
BAI 33.4 (5.2) 12.6 (3.7) 3.26 14.6 (3.1) 3.1 
PANAS-N 29.4 (4.4) 16.6 (3.8) 2.17 17 (2.4) 2.67 
PANAS-P 22.1 (3.7) 34 (4.2) 1.99 33 (4.9) 1.77 
WSAS 25 (4.1) 11.3 (3.5) 2.53 12.3 (4.3) 2.13 
RNTQ 106 (16.2) 43 (8.2) 3.47 45.3 (9.3) 3.25 
PSWQ 69.6 (11.2) 31.3 (12.4) 2.11 33 (9.4) 2.50 
Y-BOCS 33.6 (5.9) 13 (4.1) 2.86 13.6 (3.9) 2.82 
M = mean; SD = standard deviation; ADIS = Anxiety Disorders Interview Schedule; CSR = clinical severity rating; BDI=Beck 
Depression Inventory; BAI=Beck Anxiety Inventory; PANAS-P and PANAS-N=Positive and Negative Affect Scale-Positive and 
Negative subscales; WSAS=Work and Social Adjustment Scale; RNTQ=Repetitive negative thinking questionnaire. 
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Fig 1: Scores on the Positive and Negative Affect Scale-Positive and Negative subscales, Beck Depression 
Inventory and the Beck Anxiety Inventory for Patients during Baseline, Treatment and Follow-up 
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Fig 2: Scores on Standardized Measures at Pre-Treatment, Post-Treatment and Follow-Up for Each Patient 
 
 
Discussion 
 
The fundamental goal of this study was to answer one 
question: Could transdiagnostic treatment based on 
repetitive negative thinking be effective in treating the 
co-occurrence of anxiety and depressive disorders? The 
results of this case series provide preliminary evidence 
for effectiveness of this protocol for treating the co-
occurrence of anxiety and depressive disorders. 
Substantial reductions were obtained on all the main 
outcome measures at post-treatment and at one-month 
follow-up, including the predicted changes on 
repetitive negative thinking as the core transdiagnostic 
factor in emotional disorders, especially anxiety and 
depression disorders. Every participant achieved 
recovery at post-treatment and at one-month follow-up 
in (co-)principal diagnosis according to the 
standardized clinical significance criteria on the BDI-
II, Y-BOCS, PSWQ and the ADIS CSR. In terms of 
the asymptomatic criterion, all participants were 
asymptomatic at post-treatment and at one-month 
follow-up. In addition, transdiagnostic treatment based 
on repetitive negative thinking appears to be relatively  
 
time efficient and easily delivered treatment for 
multiple disorders, achieving good treatment outcomes  
in 12 hours of therapy. Interestingly, the 
transdiagnostic treatment based on repetitive negative 
thinking evidenced large treatment effect for 
improvement in general functioning on the WSAS at 
end of therapy and one-month follow-up . 
Importantly, the transdiagnostic treatment based on 
repetitive negative thinking was effective in the 
treatment of a range of anxiety and depression 
disorders, including GAD, OCD and depression, 
yielding effect sizes comparable to treatments targeting 
disorder-specific symptoms. In this study, all patients 
receiving the transdiagnostic treatment based on 
repetitive negative thinking no longer met diagnostic 
criteria for their principal and co-principal diagnosis. 
Significantly, these patients no longer met criteria for 
any clinical diagnosis at post-treatment and follow-up . 
 Transdiagnostic treatments targeting core “higher-
order” factors offer a more parsimonious approach to 
treatment planning that eliminates the need for multiple 
diagnosis-specific manuals (17). In addition, other 
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researchers have begun to consider how existing 
evidence-based therapeutic principles could be 
effectively applied transdiagnostically on a more 
empirical basis using evidence-based modules of 
behavior change procedures (15- 17, 29, 74-78). Some 
of these efforts focus on identifying and correcting 
deficits in functioning rather than focusing on cross-
cutting dimensions of psychopathology. 
In what is perhaps the most advanced effort along these 
lines, Fairburn and colleagues (79) have developed a 
transdiagnostic approach to eating disorders based on 
shared psychological dimensions of these disorders, an 
approach similar to but predating ours (13). Regardless 
of the strategy, these transdiagnostic approaches may 
not only prove to be more effective, but also have 
significant implications for broader dissemination 
efforts. More specifically, transdiagnostic treatments 
have the potential to reduce the amount of time and 
effort that is required for adequate training, a factor that 
has hindered dissemination efforts in the past (80-82). 
Also, if proved effective, these treatments may prove to 
have considerable clinical utility. Clinicians are often 
faced with the difficult task of treating individuals with 
complex clinical presentations that require them to use 
multiple protocols or to tackle several problems at 
once, with little empirical data to guide them. 
Transdiagnostic treatments may help eliminate the need 
for multiple diagnosis-specific treatment manuals and 
simplified  treatment planning. 
 
Limitation 
 
There are a number of limitations of this case series. 
First, the generalizability of the results is limited as 
only three patients were treated. However, they were 
seen in clinical practice as no one was excluded on the 
basis of comorbid disorders as it is often the case in 
randomized controlled trials. 
 A second limitation is that outcome assessment relied 
heavily on self-report measures and the therapist 
administered the only clinician rated measure, the Y-
BOCS. 
Third, treatment was delivered by only one therapist 
that may limit the generalizability of the results; 
replication with other therapists is required, but this 
was not possible in this design as it was a replication 
across patients. However, treatment was delivered by a 
relatively inexperienced cognitive therapist which may 
be a further indication of the effectiveness of 
transdiagnostic treatment based on repetitive negative 
thinking. 
Forth, this study had a large number of outcome 
measures. Due to the small sample size, it is 
acknowledged that statistically this can increase the 
chances of error. The small sample size also limits the 
degree to which the results are generalizable to a 
‘typical’ population. Nevertheless, the present results 
suggest that continuing evaluations of this new 
treatment approach are warranted . 
Thus, due to these limitations, the observed 
improvements cannot be unequivocally attributed to 
TTRNT, recommending that the future studies apply 
transdiagnostic interventions in the selective and 
comprehensive randomized controlled trial research. 
Furthermore, a long-term follow up for outcomes of 
transdiagnostic treatment based on repetitive negative 
thinking is suggested. The study of transdiagnostic 
therapy mechanism and its efficacy in the other 
disorders and problems is necessary for the procedure 
dismantling studies. Finally, it seems that more studies 
need to be conducted on transdiagnostic interventions 
to compare specific interventions and the other 
disorders with this approach. 
 
Conclusion 
 
 In conclusion, comorbidity of anxiety and depression 
disorders is a big challenge in specific cognitive-
behavioral therapies and transdiagnostic therapies are 
one of the solutions. Effectiveness of these protocols 
has been evolving and the breakthrough was the 
Barlow’s transdiagnostic protocol, which was a great 
step in empowering these therapies by reinforcing the 
theoretical foundation of pragmatic protocols. 
However, these therapies still have moderate 
effectiveness in the best condition. Reviewing 
theoretical studies, this shortage can be attributed to 
ignoring the main process in emotional disorders (i.e., 
repetitive negative thinking) and its relevant variables. 
In summary, all the three patients treated with TTRNT 
made clinically significant improvement within 12 
hours of therapy. TTRNT for co-occurrence of anxiety 
and depressive disorders could prove to be a time 
effective and efficient treatment for individuals with 
these occurrence disorders. The results of this 
preliminary investigation revealed that a controlled 
evaluation of the efficacy of TTRNT for co-occurrence 
of anxiety and depressive disorders is needed. An 
appropriate next step would be to conduct a 
randomized controlled trial comparing TTRNT and 
Barlow’s transdiagnostic protocol or a well-established 
cognitive behavioral treatment. To this end, we are 
conducting a pilot randomized controlled trial of 
TTRNT for co-occurrence of anxiety and depressive 
disorders, using the treatment manual from this study 
to more rigorously investigate the efficacy of TTRNT 
as a new form of transdiagnostic treatment. 
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